Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates $(UAE)$ Ministry of Health and Prevention seeking approval to commercialize PHEXXI®, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.